Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply

da Silva, Ines Pires; Ahmed, Tasnia; Reijers, Irene L M; Warner, Allison Betof; Patrinely, James Randall; Serra-Bellver, Patricio; Allayous, Clara; Mangana, Joanna; Zimmer, Lisa; Trojaniello, Claudia; Klein, Oliver; Gerard, Camille L; Michielin, Olivier; Haydon, Andrew; Ascierto, Paolo A; Carlino, Matteo S; Lebbe, Celeste; Lorigan, Paul; Johnson, Douglas B; Sandhu, Shahneen; Lo, Serigne N; Menzies, Alexander M; Long, Georgina V

doi:10.1016/S1470-2045(21)00419-8

Scientific article

Letter

English

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply

Published inLancet oncology, vol. 22, no. 8, p. e343-e344

Publication date2021-08

Abstract

Reply to : Li M. Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma. Lancet Oncol. 2021 Aug;22(8):e342. doi: 10.1016/S1470-2045(21)00326-0. PMID: 34339646.

Regarding : Pires da Silva I, Ahmed T, Reijers ILM, Weppler AM, Betof Warner A, Patrinely JR, Serra-Bellver P, Allayous C, Mangana J, Nguyen K, Zimmer L, Trojaniello C, Stout D, Lyle M, Klein O, Gerard CL, Michielin O, Haydon A, Ascierto PA, Carlino MS, Lebbe C, Lorigan P, Johnson DB, Sandhu S, Lo SN, Blank CU, Menzies AM, Long GV. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 2021 Jun;22(6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. PMID: 33989557. https://archive-ouverte.unige.ch/unige:191570

Keywords

Humans
Ipilimumab / adverse effects
Melanoma / drug therapy
Nivolumab / adverse effects

Affiliation entities

Not a UNIGE publication

Research groups

Découverte de biomarqueurs numériques pour l'oncologie de précision (1059)

Citation (ISO format)

DA SILVA, Ines Pires et al. Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors” reply. In: Lancet oncology, 2021, vol. 22, n° 8, p. e343–e344. doi: 10.1016/S1470-2045(21)00419-8

Article (Published version)

Identifiers

PID : unige:191584
DOI : 10.1016/S1470-2045(21)00419-8
PMID : 34339647

Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S1470204521004198

Journal ISSN1470-2045

8views

0downloads

Creation28/11/2025 17:40:10

First validation17/02/2026 08:54:24

Update24/03/2026 09:54:35

Status update24/03/2026 09:54:35

Last indexation24/03/2026 09:57:21

Archive ouverte UNIGE

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply

Technical informations